$3.18
+0.12 (+3.92%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BCAB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 1 tracked-famous manager (MILLENNIUM MANAGEMENT LLC) · FINRA short interest 4.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.NCT05808634Part 1: Assess dose limiting toxicity as defined in the protocolOpen-label · Treatment | Phase 1 | Recruiting | Drug: BA3182 | Advanced Adenocarcinoma | 168 | 2028-09-15 | in 758 d | 2025-09-25 |
| A Phase 1/2 Study of BA3071 in Patients With Solid TumorsNCT05180799Assess dose limiting toxicity as defined in the protocolNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: BA3071, Nivolumab, Pembrolizumab · Drug: Pemetrexed (Alimta) | NSCLC, Melanoma | 320 | 2025-03-19actual | — | 2025-06-15 |
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604Confirmed Objective Response Rate (ORR) per RECIST v1.1Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck | 42 | 2025-09-22actual | — | 2025-09-26 |
| CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCNCT04681131Confirmed Objective Response Rate (ORR) per RECIST v1.1Non-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: CAB-AXL-ADC, PD-1 inhibitor | Non-Small-Cell Lung Cancer | 85 | 2025-07-09actual | — | 2025-09-25 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With SarcomaNCT03425279Phase 1: Safety ProfileNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: CAB-AXL-ADC, PD-1 inhibitor | Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | 245 | 2025-01-08actual | — | 2025-09-23 |
| CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)NCT03504488Phase 1: Safety ProfileRandomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: CAB-ROR2-ADC, PD-1 inhibitor | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 132 | 2024-12-30actual | — | 2025-01-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19